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The endemic mycoses are important but often overlooked causes for community acquired
pneumonia. Delays in recognition, diagnosis and proper treatment often lead to disastrous
outcomes. This topic is not usually discussed in reviews and guidelines addressing the subject
of community acquired pneumonia. In this review we discuss the three major endemic mycoses
in North America that present as community acquired pneumonias; Coccidioidomycosis, Histo-
plasmosis and Blastomycosis. We discuss their epidemiology, clinical presentations, methods of
diagnosis and current treatment strategies.
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The endemic mycoses are important but often overlooked
causes for community acquired pneumonia (CAP). Of note is
that they often occur outside of the traditional endemic
area. For example, in a review of endemic mycoses among
the elderly, one quarter of cases of coccidioidomycosis
occurred outside the southwest United States.1 Not only are
the endemic mycoses common causes for hospitalizations,
they are often severe, fatal in nearly 10% of cases.2
Surprisingly, deaths occurred overwhelmingly (87%) in
nonimmunocompromised subjects. The failure to consider
and delay in testing for the endemic mycoses contributes to
the poor outcome.Coccidioidomycosis
Epidemiology
Coccidioidomycosis is a common fungal cause of community
acquired pneumonia in the southwest endemic areas,3e5
Table 1. Most infections are acquired through soil disrup-
tion and subsequent inhalation of airborne arthroconidia.
As such, “haboob” sand storms near Phoenix, Arizona as
well as military training exercises in California are frequent
culprits of outbreaks.
Clinical
Coccidioidomycosis mimics bacterial causes of CAP in
healthy individuals and immunocompromised patients.
About 60% of people infected are asymptomatic, and ofe 1 Epidemiologic, clinical and radiographic characteristic
meter Coccidioidomycosis
sure history Sand storms, construction,
military exercises, often dry
period following rainy seasons
ical findings Respiratory symptoms, fever,
fatigue, eosinophilia
st radiographs/CT Focal and diffuse infiltrates,
cavities, pleural effusion,
adenopathy, micronodular infiltratessymptomatic cases 95% experience a self-limited infection
that resolves after several weeks. Approximately 1% of
patients will have disseminated infection with the most
common extra thoracic sites being skin, soft tissue, bone,
and meninges.6 Symptoms of acute infection resemble
bronchitis or pneumonia and are indistinguishable from
other causes of community acquired pneumonia,3,4,7
Table 1. In retrospective studies, patients with coccidioi-
domycosis were less likely to have cough and sputum
production but more likely to have eosinophilia, pleurisy,
myalgia, rash, and fatigue than patients without coccidi-
oidomycosis.4,5 Eosinophilia occurs in a quarter of cases and
may suggest coccidioidal pneumonia or prompt further
testing. Although resolution is the norm, chronic progres-
sive, often apical cavitary pneumonia resembling tubercu-
losis may occur, and peripheral cavities can rupture causing
pneumothorax or pyopneumothorax. Pleural manifestations
are more prominent in coccidioidomycosis than other
endemic fungal diseases.
Radiographic
The radiologic findings of acute coccidioidomycosis are
diverse and nonspecific. Pulmonary infiltrates are identified
in the majority of patients, and pleural effusions and
adenopathy are common,8 Table 1. Pulmonary nodules and
cavities are identified in less than 5% of cases. Immuno-
suppressed patients may manifest a diffuse “miliary”
pattern.9 CT scans are more sensitive, identifying effusions,
hilar lymph nodes, micronodular infiltrates, and multifocal
ground glass infiltrates more readily. Mediastinal and hilar
adenopathy is common, but not to the degree that is seens.
Blastomycosis Histoplasmosis
Outdoor activity near
waterways
Exposure to soil containing
bat or bird droppings,
usually unrecognized
Respiratory symptoms,
skin or bone lesions
Respiratory symptoms, fever,
arthralgia
Lobar consolidation,
diffuse infiltrates,
nodular infiltrates
Focal, diffuse or cavitary
infiltrates, hilar or mediastinal
lymphadenopathy
Endemic mycoses CAP 771in some patients with acute histoplasmosis. Lymph nodes
and nodules exhibit varying degrees of uptake on PET scans.
Small non-calcified nodules are common residua of acute
Coccidioides that can be confused with malignancy.
Nodules may evolve into thin walled cavities by shelling out
the nodule contents. These cavities usually resolve but may
be sanctuary for secondary infection or mycetoma, or may
cause pneumothorax or hemoptysis.
Diagnosis
In a large proportion of community acquired pneumonia
patients in the endemic area, diagnostic testing for
coccidioidomycosis is not performed.3 In a large retro-
spective cohort, patients more likely to be tested for
coccidioidomycosis were adults and immunosuppressed
patients. Patients who experienced symptoms for >14
days, manifest a rash, or had chest pain were also more
likely to be tested.3
Rapid diagnosis can be achieved by cytopathologic
examination of respiratory specimens in patients with lung
infiltrates or cavitary disease, positive in one quarter10,11 to
two-thirds of cases,8,12 Table 2. Simultaneous trans-
bronchial biopsy may increase the diagnostic yield.12
Nodules may be biopsied to exclude malignancy.13 In
many patients with negative cytopathology, culture is
positive.10,11 In patients with milder illnesses, however,
cytopathology and culture are performed in only 40e60% of
cases, respectively.10 Despite the availability of more rapid
diagnostic methods, culture remains an important part of
the diagnostic workup, providing the only basis for diag-
nosis in some cases.
Serologic tests for antibodies are the most widely used
method of diagnosis and are perhaps more useful in diag-
nosing coccidioidal infection than the other endemic
mycoses. IgM specific for the tube precipitin antigen and
IgG specific for the complement fixation antigen can be
assayed locally by commercially available immunodiffusion
kits or enzyme-linked immunoassay (EIA).6 IgG antibody to
the complement fixation antigen, when positive, can be
quantified at reference laboratories and reported as a titer.
Any positive titer is considered significant and indicative of
recent infection. Titers are often followed in symptomatic
patients or patients with chronic infection to determine
treatment efficacy and resolution.
Both EIA and agar gel immunodiffusion provide results
with a quick turnaround time. However, controversy arises
over the accuracy of IgM antibodies determined by EIA:Table 2 Diagnostic tests in blastomycosis and
coccidioidomycosis.
Parameter Coccidioidomycosis Blastomycosis
Cytopathology 25e508,10,12,17,20,a 8126
Culture 40e10010e12,17,18 8626
Antibody 50e10011,12,16e18 3226
Antigenuria 50e7110,11,20 55e9326,45,76
Antigenemia 7020 8045
Antigen BAL Single case11 8077
PCR 56e10018,21 8647
a Sensitivity in percent (references).100% were judged to be true positives in one14 but 82% were
regarded as false positive in another15 report. An isolated
positive IgM should be confirmed by additional diagnostic
testing.14 Additionally, the antibody test may be falsely
negative early in the course of infection or in immunosup-
pressed patients11,12,16e18 False negative EIA was noted in
13% of healthy patients and 33% of immunosuppressed
patients, declining to 5% and 17%, respectively when
confirmatory tests were performed.16 Antibody tests also
may be negative early in the disease,16 as noted in half of
cases in one study.11 Thus, negative antibody tests cannot
exclude coccidioidomycosis.19
Coccidioides galactomannan antigen testing is available
in select reference laboratories. Antigenuria was detected
in 50% of patients with moderate20 and 71% with moderate
to severe disease, among whom tests for antibodies were
positive in 54%.10 Antigenemia was detected in 73% of
patients with mild to moderate disease, identifying an
additional 29% of cases that would have been missed if only
urine was tested.20 Thus, the greatest sensitivity may be
achieved by testing both urine and serum. Antigen also has
been detected in BAL in patients with negative results in
urine.11
Real-time PCR targeting the internal transcribed spacer
region 2 sequences exhibited a sensitivity of 100% on
respiratory samples, 93% on fresh tissue and 73% on
paraffin-embedded tissue, with a specificity of 98e100%.21
In clinical testing PCR was positive in respiratory specimens
in five of nine patients, most of whom were immunosup-
pressed and culture positive.18 The relative sensitivity of
real-time PCR and antigen detection remains to be
determined.
Management
In the context of community acquired pneumonia, the
decision of whether or not to treat with anti-fungal therapy
is based on clinical context and severity of symptoms. When
treatment is deemed necessary, azole therapy is preferred.
In most cases of acute pulmonary coccidioidomycosis pre-
senting as CAP, fluconazole or itraconazole 400 mg daily for
3e6 months is sufficient. Fluconazole is often used as
itraconazole requires closer monitoring with drug levels and
careful consideration of drug interactions.22 Longer therapy
(12e18 months) is recommended for cavitary, diffuse
pulmonary or disseminated disease.
Lipid formulation of amphotericin B is recommended in
patients with extensive, bilateral, or “miliary” pneumonia,
or disseminated disease in immunocompromised patients.
Patients are frequently transitioned to fluconazole or itra-
conazole after a week or two and therapy continued for at
least 12 months,23 Table 3. Concomitant steroid therapy
may be appropriate if paradoxical worsening or delayed
improvement occurs with anti-fungal therapy alone for
severe pulmonary coccidioidomycosis. Amphotericin should
be used in pregnancy due to concerns regarding the tera-
togenicity of azole anti-fungal agents, especially in the first
trimester.
Asymptomatic pulmonary nodules and small thin walled
cavities are not typically treated with antifungals. Occa-
sionally nodules change size and extirpate their contents.
However, they can be confused with malignancy when
a diagnosis of coccidioidomycosis was not previously
Table 3 Guidelines for treatment of endemic mycoses based on consensus group recommendations.
Parameter Coccidioidomycosis23,49 Blastomycosis27,49 Histoplasmosis49,69
Severe (ICU) Lipid amphotericin B 1e2
week then fluconazole or
itraconazole
Lipid amphotericin B,
1e2 week then
itraconazole
Lipid amphotericin B
1e2 week then itraconazolea
Moderately severe
(hospitalize)
Lipid amphotericin B 1e2
week then fluconazole or
itraconazole
Lipid amphotericin B
1e2 week then
itraconazole
Lipid amphotericin B
1e2 week then itraconazolea
Mild (not hospitalize) Fluconazole or itraconazole Itraconazole Itraconazole
a Consider systemic corticosteroids in patients with ARDS.
772 C.A. Hage et al.secured. When unclear, residual nodules frequently lead to
biopsy or excision.Blastomycosis
Epidemiology
The endemic area for blastomycosis overlaps with that of
histoplasmosis, but stretches further north into Minnesota,
Wisconsin, the Canadian provinces adjacent to the great
lakes and the areas surrounding St. Lawrence Seaway in
New York and Canada.1 Blastomycosis is less common than
histoplasmosis and coccidioidomycosis.2 Recent excavation
activity and residence near waterways are risk factors for
blastomycosis, (Table 1).24 Point source outbreaks have
been reported where most patients present with an acute
illness after heavy exposure to contaminated excavation
sites. The incubation period ranges from 21 to 106 days with
a median of 45 days.25
Clinical
The lungs are the most commonly affected organs in blas-
tomycosis.26,27 The majority of infected individuals are
either asymptomatic or manifest a mild self-limited
illness.26 Also, most patients are otherwise healthy.26 Acute
pulmonary blastomycosis is commonly seen in the setting of
an outbreak following heavy, point source exposure.
Symptoms are abrupt and include cough productive of
purulent sputum, fever, night sweats, dyspnea, chest pain,
weight loss, myalgia and occasionally hemoptysis, (Table
1). The illness is often confused with bacterial community
acquired pneumonia, and the diagnosis is suspected only
after failure to respond to antibacterial therapy.28,29 In one
series, diagnosis took more than 30 days in 43% of the cases,
with only one quarter diagnosed within a week of presen-
tation.30 The illness may rapidly progresses to acute
respiratory distress syndrome (ARDS) and shock in about
10% of cases26,31 with up to 60% mortality.28 Delays in
considering and testing for blastomycosis contribute to this
poor outcome. Severe pulmonary blastomycosis is more
common in young immunocompromised patients32,33 and
those with diabetes mellitus.28
Chronic pulmonary blastomycosis is usually gradual in
onset, and symptoms include cough productive of purulent
sputum, fever, night sweats, malaise, and weight loss.34
The illness can be mistaken for tuberculosis or lung
cancer, and is progressive if untreated.34Extrapulmonary dissemination occurs in up to third of
cases,26,35 most commonly involving skin, bone, and the
genitourinary system. Cutaneous or bone lesions in
a patient with community acquired pneumonia who resides
in the endemic area should raise the suspicion for blasto-
mycosis. Dissemination to the central nervous system may
also occur.36
Radiographic
No specific radiographic findings are characteristic enough
to suggest the diagnosis of blastomycosis. The most
common findings in acute pulmonary blastomycosis include
lobar consolidation, air bronchogram, and nodular infil-
trates,26,37,38 Table 1. Miliary nodules and interstitial infil-
trates are common in severe cases.38 Mediastinal or hilar
lymphadenopathy26 and pleural effusions are infrequent.39
Mass like lesions, often mistaken as malignancy, and cavi-
ties within areas of consolidation can be seen in chronic
cases.26
Diagnosis
The diagnosis is often delayed because of failure to
consider blastomycosis in patients with community
acquired pneumonia.30 If suspected, the diagnosis usually
can be made rapidly by microscopic visualization of the
organism or detection of antigen in body fluids,26,40 (Table
2). The yield of cytopathology ranges from 38% to
97%.26,41,42 Histopathology of lung tissue biopsy specimen
may provide a diagnosis in some cases with negative
cytology.26,43 Definitive diagnosis requires the isolation of
the organism by culture which is positive in 67e86% of
cases,26,44 often within one week of incubation.
Blastomyces antigen can be detected in serum, urine
and BAL fluid, often providing the initial basis for diag-
nosis,26,40 positive in 85%e93% of patients.26,45,46 Testing
both serum and urine may improve the sensitivity for
diagnosis by antigen detection. Cross reactions occur in
histoplasmosis (96e100%),26,45,46 paracoccidioidomycosis
(100%), and penicilliosis marneffei (70%); otherwise speci-
ficity is 98% with other mycoses (cryptococcosis, aspergil-
losis, coccidioidomycosis, and candidiasis).46
PCR methods are promising. Excellent sensitivity and
specificity was reported using a real-time method on
isolates and clinical specimen.47 This finding requires vali-
dation before the role of PCR is known.
Available tests for antibodies to Blastomyces are not
used commonly because of poor sensitivity (<50%)26 and
Endemic mycoses CAP 773specificity, however accuracy may be improved using
certain Blastomyces antigens.48
Management
Treatment is recommended unless clinical resolution has
occurred before the diagnosis is made.27,49 A lipid formu-
lation of Amphotericin B is recommended for patients with
severe or CNS disease, (Table 3). Amphotericin B is usually
administered until there is clinical improvement (1e2
weeks) except in patients with CNS diseases, in which 4e6
weeks is recommended. Itraconazole is administered for
6e12 months after discontinuation of amphotericin B.
Itraconazole is the treatment of choice for non-severe
cases.50 The recommended dose is 200 mg three times a day
for three days followed by 200 mg twice a day for at least
six months. A Longer treatment is recommended for
immunosuppressed patients, those with bone disease, and
those who relapse. Fluconazole is less effective and is not
recommended except in patients who do not tolerate
itraconazole, and then should be administered at high
doses (800 mg/day). Voriconazole has been used51 but its
role remains unclear. Corticosteroids may be useful
adjuncts to anti-fungal therapy in patients with ARDS.52,53Histoplasmosis
Epidemiology
Histoplasmosis is a community acquired infection, most
often presenting as pneumonia. Most cases are first treated
with antibiotics and the diagnosis is not suspected until
they fail to improve. Except in outbreak settings where
multiple individuals become ill following a shared activity
and present acutely with diffuse pulmonary infiltrates,
a history of exposure to sites likely to harbor Histoplasma
mold is uncommon. Some epidemiologic clues are listed in
Table 1.
Clinical
There are no unique clinical findings to alert the physician
to suspect histoplasmosis. Patients present with cough,
chest pain, fever, sweats and malaise, usually occurring
between one and three weeks following a high-inoculumTable 4 Diagnostic tests in histoplasmosis.
Parameter Acute pulmonary
histoplasmosis
Cytopathology 2/1065
0/264
Culture 8/1965
0/364
Antibody 18/2865
4/664
Antigenemia 23/2965
Antigenuria 13/2965
5/664
Antigen BAL 3/477exposure,54,55 described as the “epidemic” type of acute
pulmonary histoplasmosis, Table 1 56. Severe cases may
culminate in respiratory failure38,57 and death.57 Low-level
exposure causes mild flu-like illness often lasting for more
than a month, referred to herein as subacute pulmonary
histoplasmosis.55,58,59 Although self-limited, patients often
undergo unneeded invasive procedures, receive repeated
courses of antibiotic therapy, and miss school or work, at
a substantial cost.
Patients with underlying obstructive lung disease typi-
cally experience chronic pulmonary symptoms accompa-
nied by progressive lung infiltrates with cavitation, termed
chronic pulmonary histoplasmosis.55 Cavitation and chro-
nicity may suggest anaerobic infection, for which repeated
courses antibiotics are prescribed without clinical benefit
before histoplasmosis is suspected.
Radiographic
Chest radiographs or CT scans in acute pulmonary histo-
plasmosis show diffuse reticulonodular or miliary infil-
trates, at times accompanied by mediastinal or hilar
lymphadenopathy56 Table 4. Similar findings may be seen in
patients with progressive disseminated histoplasmosis,60
which should be suspected in the absence of an acute
exposure or the presence of immunosuppression. Findings
in subacute pulmonary histoplasmosis include hilar or
mediastinal lymphadenopathy with localized or patchy
infiltrates.55 With healing infiltrates may regress into
nodules, which eventually calcify but may cavitate.
Imaging studies in chronic pulmonary histoplasmosis show
changes of underlying emphysema, upper lobes infiltrates,
pleural thickening, volume loss and cavitation, resembling
those seen in tuberculosis.55
Diagnosis
Demonstration of yeast by cytology or histopathology may
provide a rapid diagnosis with high specificity but with
lower sensitivity than antigen or antibody detection.
Isolation of the organism by culture may provide the only
laboratory basis for diagnosis in some patients, but requires
at least one week and often up to four weeks to detect
positive results. The role of PCR remains to be determined.
Good sensitivity and specificity was reported,47 but only sixSubacute pulmonary
histoplasmosis
Chronic pulmonary
histoplasmosis
8/1964 3/464
1/1126 1/626
2/2467 0/567
14/2664 4/464
5/3426 11/1326
11/12867 11/1767
39/4164 5/664
67/6826 14/1426
151/17667 14/1567
5/2026 1/526
14/4664 4/564
22/6526 2/1426
2/278 5/577
774 C.A. Hage et al.BAL specimens and five other respiratory specimens were
tested, of which four BALs were negative. Other studies
have shown that PCR was not sensitive when testing
BAL61,62 and that PCR was less sensitive than pathology
when applied to tissues.63
Acute pulmonary histoplasmosis: Antigen detection is
the most sensitive diagnostic test in acute pulmonary
histoplasmosis (Table 4).64,65 Both urine and serum must be
tested achieve the highest sensitivity: 38% of cases would
have been missed by testing urine only, based on findings in
one study.65 The sensitivity of cytopathology of respiratory
specimens is uncertain, but probably low, based upon
a review of the findings in published studies.64,65 Serologic
tests for anti-Histoplasma antibodies are positive in about
two-thirds of cases,64,65 but not during the first three weeks
of infection, based on one report,66 when diagnosis is often
most valuable. Respiratory cultures are positive less than
half of cases.64,65
Subacute pulmonary histoplasmosis: As most patients
have been ill for more than a month before testing is per-
formed, and antibody tests are usually positive.26,64,67
Accordingly, agar gel immunodiffusion and/or comple-
ment fixing antibodies are positive in 95% of cases.64,67 The
complement fixation test is positive at titers of at least 1:8
in 90%, M bands in three quarters, and H bands in one
quarter of patients.67 CF titers of 1:8 or 1:16 are less
helpful in differentiating active from past infection, but
occur in a third of acute cases, and should not be
disregarded.
Many physicians presume antibody testing is not useful
because antibodies are present in most individuals from
endemic areas, mimicking skin test positivity. However, the
agar gel immunodiffusion was positive in only 0.5% and
complement fixation test in 4% of healthy young adults from
cities where Histoplasmin skin test positivity exceeded 50%,
usually at titers of 1:8 or 1:16, as noted in one report.67
Tests for antigenuria are positive in about one-third of
cases, histopathology or cytology in 10e40%26,64,67 and
culture in 10e50%,26,64,67 if invasive procedures are per-
formed. However, the diagnosis can usually be made by
serology, avoiding biopsies.
Chronic pulmonary histoplasmosis: Culture of respiratory
specimens, antigen testing of BAL or bronchial washings,
and tests for antibodies are most useful. Cultures were
positive in 65e85% of cases.26,64,67 Culture of sputum when
cultures of BAL and/or bronchial washings are negative.
Antibody tests are positive in over 90% of cases in most
series.26,64,67 Antigen was detected in the urine of 14% of
cases in one report26 and 80% in another, using a more
sensitive assay.64 Detection of high levels of antigenuria,
however, suggests concurrent progressive disseminated
histoplasmosis.64,68
Management
Lipid amphotericin B and itraconazole are preferred for
treatment of histoplasmosis.69 Liposomal amphotericin B
was superior to the deoxycholate formulation for treatment
of progressive disseminated histoplasmosis in patients with
the acquired immunodeficiency syndrome.70 Several
studies have established effectiveness of itraconazole for
treatment of mild to moderately severe histoplasmosis,
reviewed elsewhere.71 Itraconazole blood level monitoringis recommended as levels are highly variable.69 Drug
interactions must also be considered.
Acute pulmonary histoplasmosis: Although most patients
recover without therapy,72 the clinical findings may be
severe, recovery may be slow, and death may occur.65
Accordingly, most patients should be treated.69 The anec-
dotal experience supports treatment efficacy for acute
pulmonary histoplasmosis.65 Lipid amphotericin B is rec-
ommended in those who are hypoxic, accompanied by
corticosteroids for the first week or two.69 Patients with
milder illnesses may be treated with itraconazole alone,
200 mg once or twice daily. The optimal duration of therapy
is unknown, but a six to 12 week course is recommended.
Subacute pulmonary histoplasmosis: Most patients with
have mild symptoms and have improved by the time the
diagnosis is established. Thus, anti-fungal therapy is usually
unnecessary. Itraconazole 200 mg once or twice daily given
for six to 12 weeks may be helpful in those who remain
symptomatic for more than one month.69
Chronic pulmonary histoplasmosis: Treatment is indi-
cated in all patients with chronic pulmonary histoplas-
mosis.69 Treatment reduces symptoms, eradicates the
organism from respiratory specimens, and reduces pulmo-
nary infiltrates.73,74 Itraconazole 200 mg once or twice daily
is recommended for at least 12 months, and until the chest
imaging shows no further improvement. Relapse occurs in
about 15% of cases followed for 1e2 years.75
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